XML 42 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements on a Recurring Basis
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands):
Fair Value as of September 30, 2020Fair Value Measurements Using Inputs Considered as:
Level 1Level 2Level 3
Assets:
Derivative assets - designated as cash flow hedges (foreign currency exchange rate “FX”)$1,787 $— $1,787 $— 
Derivative assets - freestanding instruments (FX)4,052 — 4,052 — 
Derivative assets - capped call derivatives38,999 — — 38,999 
Convertible notes receivable2,301 — — 2,301 
$47,139 $— $5,839 $41,300 
Liabilities:
Derivative liabilities - freestanding instruments (interest rate swaps)$139 $— $139 $— 
Derivative liabilities - freestanding instruments (FX) 85 — 85 — 
Derivative liabilities - embedded exchange feature59,398 — — 59,398 
Derivative liabilities - other1,350 — — 1,350 
Contingent consideration arrangements96,174 — — 96,174 
$157,146 $— $224 $156,922 

Fair Value as of December 31, 2019Fair Value Measurements Using Inputs Considered as:
Level 1Level 2Level 3
Assets:
Derivative assets - designated as cash flow hedges (FX)$535 $— $535 $— 
Derivative assets - freestanding instruments (FX)26 — 26 — 
$561 $— $561 $— 
Liabilities:
Derivative liabilities - designated as cash flow hedges (FX)$169 $— $169 $— 
Derivative liabilities - designated as cash flow hedges (interest rate swaps)374 — 374 — 
Derivative liabilities - freestanding instruments (FX) 3,137 — 3,137 — 
Contingent consideration arrangements137,349 — — 137,349 
$141,029 $— $3,680 $137,349 
Reconciliation of Beginning and Ending Balances of Contingent Consideration
The following table provides a reconciliation of the beginning and ending balances of our recurring fair value measurements, using significant unobservable inputs (Level 3) (in thousands):
Capped Call Derivative AssetEmbedded Exchange Feature Derivative LiabilityOther Derivative LiabilitiesContingent Consideration Liability ArrangementsConvertible Notes Receivable
As of December 31, 2019$— $— $— $137,349 $— 
Additions43,096 74,951 — — 2,267 
Payments (1)
— — — (9,868)— 
Changes in fair value (2) (3) (4)
(4,097)(15,553)1,350 (31,176)34 
Effect of changes in foreign currency exchange rates— — — (131)— 
Total at September 30, 202038,999 59,398 1,350 96,174 2,301 
Less current portion at September 30, 2020— — 1,160 16,571 2,044 
Long-term portion at September 30, 2020$38,999 $59,398 $190 $79,603 $257 
(1)During the nine months ended September 30, 2020, we paid $8.8 million under the contingent consideration arrangement for the acquisition of CardiacAssist, Inc., doing business as TandemLife (“TandemLife”). Additionally, we made final payments under contingent consideration arrangements resulting from the acquisitions of two distributors.
(2)The contingent consideration change in fair value during the nine months ended September 30, 2020 is primarily due to a one-year delay in the projected achievement of a certain regulatory milestone and timing of sales-based earnout payments for ImThera Medical Inc. (“ImThera”), and the impact of an increase in discount rates utilized in the valuation of contingent consideration. Refer to the tables below for further information regarding the fair value measurements of contingent consideration.
(3)During the nine months ended September 30, 2020, the contingent consideration change in fair value resulted in a decrease of $19.2 million and $12.0 million recorded to cost of sales - exclusive of amortization and research and development, respectively.
(4)Changes in the fair value of the embedded exchange feature derivative and capped call derivatives are recognized in foreign exchange and other gains (losses) in the condensed consolidated statements of income (loss).
Schedule of Business Acquisitions by Acquisition, Contingent Consideration
The following table provides the fair value of our Level 3 contingent consideration arrangements by acquisition (in thousands):
September 30, 2020December 31, 2019
ImThera$79,603 $113,503 
TandemLife11,672 17,311 
Miami Instruments4,899 5,338 
Drilltex— 294 
Other— 903 
$96,174 $137,349 
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Both arrangements are Level 3 fair value measurements and include the following significant unobservable inputs as of September 30, 2020:
ImThera AcquisitionValuation TechniqueUnobservable InputRanges
Regulatory milestone-based paymentDiscounted cash flowDiscount rate8.3%
Probability of payment85%
Projected payment year2024
Sales-based earnoutMonte Carlo simulationRisk-adjusted discount rate12.2 %-12.5%
Credit risk discount rate8.5 % -9.2%
Revenue volatility32.5%
Probability of payment85%
Projected years of earnout2025-2028
The TandemLife business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain regulatory milestones. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of September 30, 2020:
TandemLife AcquisitionValuation TechniqueUnobservable InputRanges
Regulatory milestone-based paymentDiscounted cash flowDiscount rate7.6 %-7.7%
Probability of payments70 %-100%
Projected payment years2020-2021
The Miami Instruments business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain regulatory milestones. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of September 30, 2020:
Miami InstrumentsValuation TechniqueUnobservable InputRanges
Regulatory milestone-based paymentsDiscounted cash flowDiscount rate7.6 %-7.7%
Probability of payments80 %-95%
Projected payment years2020 -2021